In January 2021, QuantuMDx Group, a key molecular diagnostics market player, invested a sum of more than £11 million to ramp up production for mass manufacturing Q-POC, the company’s flagship diagnostic device.

The product is a portable, PCR device that provides sample-to-answer, rapid, and molecular diagnostic testing at the point of care, and gives results in nearly 30 minutes. The Q-POC system includes a single use test cassette, sample collection kit, and analyzer.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/434

The device’s first commercial assay will diagnose SARS-CoV-2, the virus causing Flu A & B as well as COVID-19, and offers a rapid, powerful PCR surveillance and diagnostics tool for public health officials and clinicians. Similar developments are expected to underscore the importance of molecular diagnostics over the forthcoming years.

On this note, the global molecular diagnostics market is projected to register significant gains through 2026, according to the latest research by GMI

This upsurge is attributed to the recent advances in molecular diagnostic techniques that are shifting from basic research towards clinical reality. Some of the cost-efficient and popular diagnostic tests in medicine are based on the quantification of a specific protein and are often deployed in hospitals at the global level.

Few major trends boosting molecular diagnostics market growth comprise:

Increasing demand for genetic testing

There is a high demand for genetic testing owing to the extensive scope of applications for the detection of rare disorders. The genetic testing segment in the molecular diagnostics industry registered a commendable CAGR of nearly 11 per cent over 2019-2020.

This is mainly due to the surging advancements in molecular diagnostic techniques that provide higher specificity and sensitivity. Various applications of clinical genetic testing comprise pharmacogenetic testing for guiding individual drug dosage, selection, and response; diagnostic and carrier testing for inherited disorders; screening of newborn individuals for highly penetrant disorders; and others.

Surging awareness regarding molecular diagnostics in Latin America

Latin America is witnessing increased awareness regarding numerous cost-effective molecular diagnostics alternatives. This has been instrumental in pushing the growth of the Latin America molecular diagnostics industry, which is estimated to reach a valuation of over USD 1 billion by 2026.

Deployed in areas such as patient stratification, therapeutic monitoring, drug regimen selection, and toxicity avoidance, molecular diagnostics has emerged as an integral part of disease management and therapy, bolstering the regional business landscape through the ensuing years.

Request for customization @ https://www.decresearch.com/roc/434

Rising adoption of in-situ hybridization

In-situ hybridization is a method that enables the localization of a specific nucleic acid segment within a historic section. The in situ hybridization (ISH) segment in the molecular diagnostics industry is expected to surpass USD $3 billion through 2026.

This is on account of soaring advancements in technology that enable low cost gene mapping and diagnostics. The fundamental basis of the ISH technique is that nucleic acids when preserved in an effective manner within a historic specimen, could be discovered by applying a corresponding nucleic acid strand that has a reporter molecule attached to it. The technique is primarily useful in neuroscience.

In a nutshell, the increasing dependence of families and patients on molecular diagnoses for disease prognosis, healthcare management, and family planning is expected to stimulate molecular diagnostics market growth over the forecasted span.